There are 805 resources available
110P - Longitudinal measurements of the neutrophil-lymphocyte ratio during treatment for locally advanced rectal cancer and associations with smoking, ethnicity and pathological response
Presenter: Nancy Huang
Session: Poster Display session
Resources:
Abstract
111P - Real-world experience with trifluridine–tipiracil and bevacizumab combination with an alternate schedule in refractory metastatic colorectal cancer
Presenter: Padmini S N
Session: Poster Display session
Resources:
Abstract
112P - Comparative treatment between pembrolizumab and chemotherapy on patients diagnosed with mismatch repair deficient colorectal cancer: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display session
Resources:
Abstract
113P - Associating factors of capecitabine-induced hand-foot syndrome in patients with colorectal cancer: What and how impactful?
Presenter: Aissarapong Sirichavaroj
Session: Poster Display session
Resources:
Abstract
114P - Impact of elevated CEA level on the clinicopathological features of colorectal cancer patients
Presenter: Ahmed Almezaine
Session: Poster Display session
Resources:
Abstract
115P - Optimal first-line chemotherapy for the elderly with metastatic colorectal cancer, based on the real-world data
Presenter: Naomi Sugimura
Session: Poster Display session
Resources:
Abstract
116P - Ripretinib used for preoperative treatment of metastatic gastrointestinal stromal tumor after failure of imatinib therapy
Presenter: linxi Yang
Session: Poster Display session
Resources:
Abstract
117TiP - Safety and efficacy of reduced-port laparoscopic surgery for patients with colon and upper rectal cancer: A multicenter, prospective, randomized phase III study
Presenter: Zhimin Liu
Session: Poster Display session
Resources:
Abstract
118TiP - Neoadjuvant CAPOX plus SCT510 (bevacizumab biosimilar) and finotonlimab in high-risk resectable colorectal liver metastases (CRLM): A multicenter, phase II study
Presenter: Wensheng Qiu
Session: Poster Display session
Resources:
Abstract
119TiP - A randomized, controlled, multicenter phase III study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer
Presenter: Rui-Hua Xu
Session: Poster Display session
Resources:
Abstract